Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa

Akari Shigemi, Kazuaki Matsumoto, Keiko Yaji, Yoshihiro Shimodozono, Yasuo Takeda, Hiroaki Miyanohara, Hideki Kawamura, Michiyo Orita, Koichi Tokuda, Junichiro Nishi, Katsushi Yamada

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa. In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [r = -0.823, 95% confidence interval (CI) -0.035 to -0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility (r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.

Original languageEnglish
Pages (from-to)589-591
Number of pages3
JournalInternational Journal of Antimicrobial Agents
Volume34
Issue number6
DOIs
Publication statusPublished - 2009 Dec
Externally publishedYes

Fingerprint

meropenem
doripenem
Carbapenems
Pseudomonas aeruginosa
Incidence
biapenem
Confidence Intervals

Keywords

  • Antimicrobial use density
  • Carbapenems
  • Cross-resistance
  • Pseudomonas aeruginosa
  • Susceptibility

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. / Shigemi, Akari; Matsumoto, Kazuaki; Yaji, Keiko; Shimodozono, Yoshihiro; Takeda, Yasuo; Miyanohara, Hiroaki; Kawamura, Hideki; Orita, Michiyo; Tokuda, Koichi; Nishi, Junichiro; Yamada, Katsushi.

In: International Journal of Antimicrobial Agents, Vol. 34, No. 6, 12.2009, p. 589-591.

Research output: Contribution to journalArticle

Shigemi, A, Matsumoto, K, Yaji, K, Shimodozono, Y, Takeda, Y, Miyanohara, H, Kawamura, H, Orita, M, Tokuda, K, Nishi, J & Yamada, K 2009, 'Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa', International Journal of Antimicrobial Agents, vol. 34, no. 6, pp. 589-591. https://doi.org/10.1016/j.ijantimicag.2009.07.017
Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi. / Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. In: International Journal of Antimicrobial Agents. 2009 ; Vol. 34, No. 6. pp. 589-591.
@article{dca79663903d4869a15eabb75ff63f40,
title = "Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa",
abstract = "Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa. In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [r = -0.823, 95{\%} confidence interval (CI) -0.035 to -0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility (r = 0.839, 95{\%} CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6{\%} of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3{\%} of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.",
keywords = "Antimicrobial use density, Carbapenems, Cross-resistance, Pseudomonas aeruginosa, Susceptibility",
author = "Akari Shigemi and Kazuaki Matsumoto and Keiko Yaji and Yoshihiro Shimodozono and Yasuo Takeda and Hiroaki Miyanohara and Hideki Kawamura and Michiyo Orita and Koichi Tokuda and Junichiro Nishi and Katsushi Yamada",
year = "2009",
month = "12",
doi = "10.1016/j.ijantimicag.2009.07.017",
language = "English",
volume = "34",
pages = "589--591",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa

AU - Shigemi, Akari

AU - Matsumoto, Kazuaki

AU - Yaji, Keiko

AU - Shimodozono, Yoshihiro

AU - Takeda, Yasuo

AU - Miyanohara, Hiroaki

AU - Kawamura, Hideki

AU - Orita, Michiyo

AU - Tokuda, Koichi

AU - Nishi, Junichiro

AU - Yamada, Katsushi

PY - 2009/12

Y1 - 2009/12

N2 - Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa. In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [r = -0.823, 95% confidence interval (CI) -0.035 to -0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility (r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.

AB - Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa. In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [r = -0.823, 95% confidence interval (CI) -0.035 to -0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility (r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.

KW - Antimicrobial use density

KW - Carbapenems

KW - Cross-resistance

KW - Pseudomonas aeruginosa

KW - Susceptibility

UR - http://www.scopus.com/inward/record.url?scp=70350397040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350397040&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2009.07.017

DO - 10.1016/j.ijantimicag.2009.07.017

M3 - Article

C2 - 19748231

AN - SCOPUS:70350397040

VL - 34

SP - 589

EP - 591

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 6

ER -